UniProt P20794 · PDB · AlphaFold · Substrate: MBP · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 95.7% | 4.3% | 91.48 | 0.563 |
| 2 | Pacritinib | 90.4% | 9.6% | 88.64 | 0.452 |
| 3 | Pralsetinib | 69.8% | 30.2% | 93.43 | 0.643 |
| 4 | Defactinib | 54.4% | 45.6% | 92.68 | 0.450 |
| 5 | Vemurafenib | 52.1% | 47.9% | 96.49 | 0.598 |
| 6 | Brigatinib | 36.8% | 63.2% | 82.96 | 0.513 |
| 7 | Pexidartinib | 31.7% | 68.3% | 99.49 | 0.631 |
| 8 | Fedratinib | 23.8% | 76.2% | 96.21 | 0.576 |
| 9 | Sunitinib | 22.0% | 78.0% | 91.73 | 0.524 |
| 10 | Entrectinib | 19.7% | 80.3% | 93.69 | 0.671 |
| 11 | Midostaurin | 16.2% | 83.8% | 78.64 | 0.500 |
| 12 | Alpelisib | 15.6% | 84.4% | 97.22 | 0.720 |
| 13 | Dabrafenib | 14.0% | 86.0% | 94.74 | 0.633 |
| 14 | Baricitinib | 13.4% | 86.6% | 97.99 | 0.616 |
| 15 | Pazopanib | 12.5% | 87.5% | 97.49 | 0.672 |
| 16 | Lorlatinib | 12.1% | 87.9% | 97.24 | 0.694 |
| 17 | Ceritinib | 12.1% | 87.9% | 95.44 | 0.618 |
| 18 | Dacomitinib | 12.0% | 88.0% | 97.99 | 0.664 |
| 19 | Rabusertib | 11.3% | 88.7% | 98.74 | 0.687 |
| 20 | Ruxolitinib | 11.2% | 88.8% | 98.25 | 0.592 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.10
- Epithelial log2(TPM+1): 0.24
- Fold change: -0.13
- Status: No significant change
High-confidence drugs
- Abemaciclib — inh 95.7% · KISS 32.81
- Pacritinib — inh 90.4% · KISS 20.52
- Pralsetinib — inh 69.8% · KISS 9.89
Selectivity landscape vs inhibition on MAK
Each point is one of the 92 approved drugs; color = inhibition % on MAK.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…